[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhejiang Provincial People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":583},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,49,80,103,132,156,177,196,216,238,266,290,307,329,349,369,394,413,434,456,473,493,513,535,558],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100598211",false,"NCT07068542","Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer","A Multicenter, Multi-Cohort, Phase II Study of Sacituzumab Tirumotecan With or Without Tislelizumab in Patients With Advanced Thyroid Cancer","Inclusion Criteria\n\nParticipants must meet all of the following criteria:\n\n1\\. Age ≥ 18 years at the time of informed consent. 2. Histologically confirmed unresectable, locally advanced, or metastatic:\n\n* Anaplastic thyroid carcinoma (ATC), or\n* Poorly differentiated thyroid carcinoma (PDTC), or\n* Radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC), including papillary thyroid carcinoma or follicular thyroid carcinoma and variants.\n\n  3\\. For ATC or PDTC:\n* No BRAF V600E mutation, RET fusion, NTRK fusion, or ALK fusion;\n* Or harboring such alterations but have failed prior standard first-line targeted therapy.\n\n  4\\. For RAIR-DTC: Disease must be refractory to radioactive iodine (RAI), defined as at least one of the following:\n* No RAI uptake in measurable lesions;\n* Radiographic progression within 12 months after RAI therapy;\n* Cumulative RAI dose \\>600 mCi (or iodine-equivalent);\n* Fluorodeoxyglucose (FDG)-avid measurable disease;\n* Failure of prior multi-target tyrosine kinase inhibitor (TKI) therapy. 5. At least one measurable lesion per RECIST version 1.1. 6. ECOG performance status 0-2. 7. Life expectancy ≥ 12 weeks. 8. Adequate hematologic function:\n* Absolute neutrophil count ≥ 1.2 × 10⁹\u002FL\n* Platelet count ≥ 100 × 10⁹\u002FL\n* Hemoglobin ≥ 90 g\u002FL 9. Adequate hepatic function:\n* AST and ALT ≤ 2.5 × upper limit of normal (ULN)\n* ≤ 5 × ULN if liver metastases present\n* Total bilirubin ≤ 1.5 × ULN 10. Adequate renal function:\n* Creatinine clearance ≥ 60 mL\u002Fmin (Cockcroft-Gault formula)\n\n  1. No active autoimmune disease requiring systemic therapy.\n  2. No concurrent active malignancy requiring treatment.\n  3. Willing and able to provide written informed consent.\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. Prior therapy targeting TROP2.\n2. Prior treatment with any topoisomerase I inhibitor antibody-drug conjugate.\n3. Prior immune checkpoint agonists (e.g., ICOS, CD40, CD137, GITR, OX40) or immune cell therapy.\n4. Another malignancy within 3 years prior to first dose, except adequately treated localized cancers (e.g., basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma in situ of the cervix).\n5. Uncontrolled or symptomatic central nervous system metastases.\n\n   * Patients with treated and stable CNS disease for ≥4 weeks and off corticosteroids for ≥2 weeks may be eligible.\n6. Significant uncontrolled comorbidities including, but not limited to:\n\n   * Uncontrolled hypertension\n   * Severe diabetes mellitus\n   * Active infection\n7. History of interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroids, or current suspected ILD.\n8. Unresolved toxicities from prior anti-cancer therapy greater than Grade 1 (CTCAE v5.0), except alopecia or other clinically insignificant toxicities.\n9. Active autoimmune disease requiring systemic treatment within the past 2 years (excluding hormone replacement therapy such as levothyroxine or physiologic corticosteroids).\n10. Systemic corticosteroid use \\>10 mg\u002Fday prednisone equivalent within 10 days prior to first dose (except inhaled, topical, or physiologic replacement doses).\n11. Known HIV infection or AIDS. Active syphilis infection.\n12. History of allogeneic organ transplantation or hematopoietic stem cell transplantation.\n13. Known severe hypersensitivity to study drugs or components.\n14. Chemotherapy, radiotherapy, immunotherapy, biologic therapy, TKI, or systemic immune stimulation within protocol-defined washout period prior to first dose.\n15. Pregnant or breastfeeding women.\n16. Severe ocular disorders that may interfere with corneal healing (e.g., severe dry eye syndrome, severe meibomian gland disease).","ALL","18 Years",{"count":19,"type":20},94,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a multicenter, open-label, multi-cohort Phase II exploratory study designed to evaluate the efficacy and safety of sacituzumab tirumotecan with or without tislelizumab in patients with unresectable, locally advanced, or metastatic anaplastic thyroid carcinoma (ATC), poorly differentiated thyroid carcinoma (PDTC), or radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC).\n\nPatients with ATC will receive sacituzumab tirumotecan in combination with tislelizumab. Patients with PDTC and RAIR-DTC will receive sacituzumab tirumotecan monotherapy.\n\nThe primary objective in the ATC cohort is overall survival (OS). In the PDTC and RAIR-DTC cohorts, the primary objective is progression-free survival (PFS) assessed by investigators per RECIST v1.1.",[26,27,28],"Advanced Thyroid Carcinoma","Radioiodine-refractory Differentiated Thyroid Cancer","Poorly Differentiated Thyroid Carcinoma",[30,31,32,33,34,28,35],"radioiodine-refractory differentiated thyroid cancer","Sacituzumab tirumotecan","immunotherapy","TROP2","anaplastic thyroid carcinoma","Tislelizumab","RECRUITING","2026-05-27",{"date":39,"type":40},"2026-06-01","ACTUAL",{"date":42,"type":40},"2025-07-01",{"date":44,"type":20},"2028-12-31",{"name":46,"class":47},"Zhejiang Provincial People's Hospital","OTHER",1,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100635743","NCT07556653","Allogeneic WTX-212C in Advanced Solid Tumors","A Multicenter, Open-label, Single-arm Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Allogeneic WTX-212C Engineered Red Blood Cell Injection in Patients With Advanced Solid Tumors","WTX-212C-IIT","Inclusion Criteria:\n\n* Age 18-75 years\n* Histologically or cytologically confirmed advanced solid tumors\n* At least one measurable lesion per RECIST 1.1\n* ECOG performance status ≤1\n* Adequate organ function\n* Life expectancy ≥12 weeks\n\nExclusion Criteria:\n\n* Uncontrolled serious medical conditions\n* Active or uncontrolled infections\n* Symptomatic or unstable CNS metastases\n* History of severe hypersensitivity to biologic agents\n* Autoimmune diseases requiring systemic treatment\n* Prior severe immune-related adverse events\n* Conditions affecting red blood cell integrity","75 Years",{"count":58,"type":20},24,[60],"EARLY_PHASE1","This is a multicenter, open-label, single-arm Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of allogeneic WTX-212C, an investigational allogeneic engineered red blood cell (RBC)-based product, in patients with advanced solid tumors who have failed standard therapies or have no available standard treatment options.\n\nThe study consists of a dose-escalation phase using a 3+3 design followed by a dose-expansion phase. Participants will receive allogeneic WTX-212C via intravenous infusion. Tumor assessments will be performed every 6 weeks according to RECIST 1.1.",[63],"Advanced Solid Tumors",[65,66,67,68,69,70],"Engineered Red Blood Cells","Immunotherapy","Phase I","Solid Tumor","Allogeneic Engineered Red Blood Cell","uRBC","NOT_YET_RECRUITING","2026-04-21",{"date":74,"type":40},"2026-04-29",{"date":76,"type":20},"2026-04-10",{"date":78,"type":20},"2028-04-09",{"name":46,"class":47},{"id":81,"slug":4,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":48},"100630695","NCT07491016","Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis","A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)","Inclusion Criteria:\n\n* 1\\. Age 18-85 years\n* 2\\. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria\n* 3\\. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological\u002Ftargeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients\n* 4\\. Voluntarily provided written informed consent\n\nExclusion Criteria:\n\n* 1\\. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)\n* 2\\. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)\n* 3\\. History of allergy\u002Fhypersensitivity to the study medications (Telitacicept or Tofacitinib)\n* 4\\. Active tuberculosis or active infectious diseases requiring systemic treatment\n* 5\\. Pregnancy, lactation, or refusal to use contraception during the study\n* 6\\. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due\n* to:Non-adherence or Severe adverse reactions\n* 7\\. Other conditions contraindicating participation per investigator judgment","85 Years",{"count":88,"type":20},30,"OBSERVATIONAL","The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients",[92,93,94],"Telitacicept","Treatment Compliance","Rheumatoid Arthritis","2026-03-24",{"date":97,"type":40},"2026-03-30",{"date":99,"type":20},"2026-03-01",{"date":101,"type":20},"2028-03-30",{"name":46,"class":47},{"id":104,"slug":4,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":114,"conditions":115,"keywords":121,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":48},"100616961","NCT07312422","LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","An Open-label, Single-center, Single-arm Study to Evaluate the Efficacy and Safety of Low-dose Radiation Therapy Combined With Pultelimab and Standard Treatment in Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of gender;\n* ECOG score of 0 to 1;\n* Patients with histologically or cytologically confirmed pancreatic malignancy;\n* No prior treatment with PD-1 or PD-L1 inhibitors;\n* Presence of a radiotherapeutically eligible target lesion (excluding bone metastases);\n* Subjects voluntarily participate in the study and provide signed informed consent.\n\nExclusion Criteria:\n\n* Previous history of radiotherapy;\n* Uncontrolled chronic infectious or non-infectious diseases, including but not limited to: medication-refractory heart failure, poorly controlled hypertension, etc.;\n* Active or clinically uncontrolled severe infections;\n* History of psychoactive drug abuse that cannot be abstained from, or patients with psychiatric disorders;\n* Pregnant or lactating women, or patients of childbearing potential who are unwilling or unable to adopt effective contraceptive measures;\n* Other conditions deemed by the investigator as potentially affecting the conduct of the clinical study or the interpretation of study results.",{"count":110,"type":20},10,[112,113],"PHASE1","PHASE2","To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine.",[116,117,118,119,120],"Pancreatic Cancer","PD-L1","PD-1 Inhibitor","LDRT","Proterizumab",[122,123,119,32],"pancreatic cancer","PD-1 inhibitor","2026-01-22",{"date":126,"type":40},"2026-01-26",{"date":128,"type":40},"2025-09-30",{"date":130,"type":20},"2026-10-30",{"name":46,"class":47},{"id":133,"slug":4,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":48},"100619096","NCT07340177","Xiaojin Pill\u002FNeixiao Luoli Pill for the Treatment of Thyroid Nodules","An Open-label, Multicenter, Randomized Controlled Clinical Trial of Xiaojin Pill\u002FNeixiao Luoli Pill for the Treatment of Thyroid Nodules","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosed with single or multiple thyroid nodules confirmed by high-resolution ultrasound, with at least one measurable nodule.\n* Thyroid nodules meeting one of the following criteria:\n* ACR TI-RADS category 3 with a maximum nodule diameter ≥ 1.0 cm; or\n* ACR TI-RADS category 4 or 5 nodules evaluated by fine-needle aspiration and assessed as low-risk papillary thyroid carcinoma, suitable for active surveillance, with patient consent.\n* Normal thyroid function at baseline, defined as thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) within the reference range.\n* Traditional Chinese medicine (TCM) syndrome differentiation consistent with liver qi stagnation, blood stasis, or phlegm-dampness syndrome.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Thyroid nodules confirmed as malignant or follicular neoplasms requiring surgical intervention, or assessed by the investigator as unsuitable for active surveillance.\n* Presence of hyperthyroidism or hypothyroidism, defined as abnormal TSH, FT3, or FT4 levels.\n* History of severe cardiovascular, hepatic, renal, hematologic, psychiatric, autoimmune diseases, or other malignancies.\n* Pregnant or breastfeeding women, or women planning pregnancy during the study period.\n* Known allergy or hypersensitivity to Xiaojin Pill, Neixiao Luoli Pill, placebo components, or any ingredients of the study medications.\n* Receipt of thyroid-related surgery, radiofrequency ablation, laser ablation, radioactive iodine therapy, or other treatments that may affect thyroid nodules within 3 months prior to enrollment.\n* Current use of medications known to affect thyroid function or thyroid nodules, such as amiodarone or lithium.\n* Poor treatment compliance or inability to complete follow-up as judged by the investigator.\n* Participation in another clinical trial during the study period.","65 Years",{"count":140,"type":20},108,[142],"PHASE4","The goal of this clinical trial is to learn whether Xiaojin Pill or Neixiao Luoli Pill can safely treat thyroid nodules in adults aged 18 to 65 years with benign or low-risk thyroid nodules. The main questions it aims to answer are:\n\n* Does treatment with Xiaojin Pill or Neixiao Luoli Pill lower the size of thyroid nodules compared with lifestyle intervention alone?\n* Do Xiaojin Pill or Neixiao Luoli Pill improve thyroid nodule-related symptoms and ultrasound findings while remaining safe to use?\n\nResearchers will compare lifestyle intervention plus Xiaojin Pill, lifestyle intervention plus Neixiao Luoli Pill, and lifestyle intervention alone to see if adding Xiaojin Pill or Neixiao Luoli Pill works better than lifestyle intervention by itself.\n\nParticipants will:\n\n* Be randomly assigned to one of the three study groups;\n* Receive lifestyle intervention guidance throughout the study;\n* Take Xiaojin Pill, Neixiao Luoli Pill, or no study medicine for 12 weeks, depending on their group;\n* Attend follow-up visits that include thyroid ultrasound exams, blood tests to check thyroid function and safety, and symptom assessments.",[145],"Thyroid Nodules",[147],"Thyroid nodule","2026-01-05",{"date":150,"type":40},"2026-01-14",{"date":152,"type":20},"2026-03",{"date":154,"type":20},"2027-06",{"name":46,"class":47},{"id":157,"slug":4,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":56,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100609288","NCT07212634","Cerebellar Transcranial Direct Current Stimulation for Dysphagia After Supratentorial Stroke","Efficacy and Mechanisms of Cerebellar Transcranial Direct Current Stimulation for Treating Dysphagia After Supratentorial Stroke","Inclusion Criteria:\n\n1. Patients with supratentorial stroke, confirmed by cranial MRI or CT as having cerebral infarction or hemorrhage;\n2. Stable vital signs after conventional treatment, with disease duration between 1 and 6 months;\n3. 30 ≤ age ≤75 years, male or female;\n4. Presence of dysphagia, drinking-induced coughing, and a Kubota Water Drinking Test grade of 3-5;\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. MRI-confirmed lesion involving the cerebellum;\n2. Unstable vital signs;\n3. Significant cognitive impairment (MMSE score ≤ 24);\n4. Presence of swallowing apraxia;\n5. Unwilling or unable to cooperate with treatment, or taking any medication that may affect swallowing function or nervous system activity.","30 Years",{"count":164,"type":20},76,[23],"It is estimated that 400,000 to 800,000 people worldwide develop neurogenic dysphagia annually. Stroke represents the most common etiology, with approximately 65% of acute stroke patients experiencing pharyngeal swallowing difficulties. Clinical manifestations of dysphagia vary widely in severity and may include residue, reflux, delayed swallowing initiation, aspiration, and cricopharyngeal muscle dysfunction. Due to its detrimental effects on nutrition, respiration, and psychosocial well-being, dysphagia significantly impairs patients' quality of life. Furthermore, the inability to swallow safely and efficiently can lead to serious complications such as aspiration pneumonia, malnutrition, and depression. The traditional swallowing rehabilitation treatment has limited effect in clinical practice, which makes it necessary to search for new effective swallowing methods.\n\nConventional swallowing rehabilitation often yields limited clinical benefits, highlighting the urgent need for more effective therapeutic strategies. Transcranial direct current stimulation (tDCS) is a non-invasive and safe neuromodulation technique that has shown promise in the field of neurorehabilitation. Its mechanisms extend beyond immediate cortical modulation and cerebral blood flow changes to include the regulation of synaptic plasticity, neurotransmitters such as glutamate and GABA, and excitability in remote subcortical regions. In recent years, tDCS has been increasingly applied to various neurological disorders, including post-stroke motor impairment, dysphagia, aphasia, depression, addiction, and spinal cord injury-related movement disorders. Currently, tDCS is being explored to elucidate its regulatory effects on cerebellar swallowing control, positioning it as a potential innovative treatment for neurogenic dysphagia.",[168],"Dysphagia After Stroke","2025-10-01",{"date":171,"type":40},"2025-10-08",{"date":173,"type":20},"2025-12-01",{"date":175,"type":20},"2027-12-31",{"name":46,"class":47},{"id":178,"slug":4,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":48},"100584339","NCT06888050","Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Age between 18 and 75 years old.\n* Diagnosed with type 2 diabetes according to WHO diagnostic criteria, with HbA1c between 7% and 9% at this examination, fasting venous blood glucose ≤ 11.1 mmol\u002FL, and BMI ≥ 18.5 kg\u002Fm2; known disease duration ≤ 24 months.\n* Voluntary participation in this study and signing of the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subjects), a witness must be present to observe the informed consent process and sign the informed consent form on their behalf.\n* No previous use of hypoglycemic drugs.\n\nExclusion Criteria:\n\n* Type 1 diabetes.\n* Participants who have participated in other clinical trials of diabetes treatment drugs before the start of this study.\n* Those who have experienced diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar non-ketotic coma within the past six months and required hospitalization.\n* Those who have experienced decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, undergone cardiac surgery or vascular reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) within the past six months.\n* Those taking glucocorticoid drugs (excluding topical or inhaled medications).\n* Those with a life expectancy of less than one year due to malignant tumors, active tuberculosis, or acute infections.\n* Those with clinically significant urinary tract or genital infections, or a history of recurrent urinary tract or genital infections.\n* Those with a history of hypertension whose blood pressure has not been effectively controlled despite antihypertensive drug treatment: systolic blood pressure (SBP) \\> 160 mmHg and\u002For diastolic blood pressure (DBP) \\> 100 mmHg.\n* Those with liver and kidney function indicators meeting the following criteria: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≥ 3.0×ULN; estimated glomerular filtration rate (eGFR) \\\u003C 45 ml\u002Fmin\u002F1.73 m² (calculated according to the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] formula).\n* Those allergic to the investigational drug or its components.\n* Pregnant or lactating women and those with the intention to conceive within three months of the last dose.\n* Other patients deemed unsuitable for participation in this clinical trial by the investigator.",{"count":183,"type":20},268,[142],"This multicenter, randomized controlled trial aims to evaluate the efficacy and safety of Henagliflozin-Metformin Sustained-Release Tablets (I) versus Metformin Tablets in newly diagnosed type 2 diabetes mellitus (T2DM). A total of 268 participants will be randomized (1:1) into two groups: the experimental group receiving Henagliflozin-Metformin Sustained-Release Tablets (I) (5mg\u002F500mg, once daily) with lifestyle intervention, and the control group receiving Metformin Tablets (500mg, twice daily) with lifestyle intervention. The primary outcome is the change in glycated hemoglobin (HbA1c) from baseline at 24 weeks. Secondary outcomes include changes in fasting\u002Fpostprandial blood glucose, body weight, metabolic parameters, diabetes remission rate, and safety assessments. This trial will provide evidence for early combination therapy in newly diagnosed T2DM patients.",[187],"New-onset Type 2 Diabetes","2025-09-10",{"date":190,"type":40},"2025-09-12",{"date":192,"type":40},"2025-04-11",{"date":194,"type":20},"2026-12-30",{"name":46,"class":47},{"id":197,"slug":4,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":215},"100473559","NCT05446467","Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC","Safety and Efficacy of Pembrolizumab in Combination With Low-dose PF (Cisplatin and 5-Fluorouracil) as Neoadjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma: a Multi-center, Single-arm Clinical Study Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old, ≤ 85 years old\n2. Histologically or cytologically proven squamous cell carcinoma of the head and neck; Patients diagnosed with head and neck squamous cell carcinoma with stage III and IV A without distant metastasis according to AJCC staging (8th editon), including squamous cell carcinoma of oropharyngeal (P16-), oral cavity, hypopharyngeal and larynx\n3. Measurable primary lesions per RECIST 1.1 criteria\n4. Treatment-naive patients without any previous disease-related therapy (except for diagnostic biopsies on primary lesions)\n5. ECOG performance status of 0 or 1\n6. Selective standard surgery+ standard adjuvant chemo-radiotherapy\u002Fradiotherapy as judged by the investigator\n7. No active autoimmune disease\n8. No concurrent malignancy\n9. Life expectancy is estimated to be over 3 months\n10. Have sufficient tumour tissue samples available for CPS PD-L1 immunohistochemical examination (22C3 DAKO)\n11. No abvious signs of hematological disorders, ANC≥1.5×109 \u002FL, platelets ≥100×109 \u002FL, Hb≥ 90 g\u002FL,WBC ≥3.0×109 \u002FL before enrollment, no blood transfusion and bleeding tendency within 7 days\n12. ALT,AST and ALP ≤ 2.5 × upper limit of normal (ULN); Serum bilirubin ≤ 1.5 × ULN, for patients with known Gilbert disease, serum bilirubin ≤ 3 x ULN\n13. Serum creatinine ≤1.5 or creatinine clearance\\>50 mL\u002Fmin\n14. HPV status determined by p16 IHC, in situ hybridization, or by polymerase chain reaction-based assays\n15. Able to understand this study, patient and (or) legal representative voluntarily agree to participate in this trial and sign informed consent\n\nExclusion Criteria:\n\n1. Multiple organs failure\n2. HPV p16 positive oropharyngeal cancer\n3. Patients with local advanced head and neck squamous cell carcinoma stage T4B and\u002For N3\n4. Patients with distant metastasis\n5. Uncontrolled serious diseases that, as assessed by investigator, may affect the subject's treatment with the study protocol, such as serious heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.\n6. Diagnosis of dementia, altered mental status or any mental illness that would prevent subjects understanding or giving informed consent or completing questionnaires\n7. Subjects with ≥ Grade 2 peripheral neuropathy according to CTCAE V5.0\n8. Subjects with ≥ Grade 2 hearing impairment according to CTCAE V5.0\n9. History of allergy or hypersensitivity to any of the therapeutic ingredients\n10. Diagnosis of malignancy within 5 years prior to screening, including HNSCC (other than current HNSCC) and other malignancies; Eligibility is achieved if all of the following criteria are met: malignancies received curative therapy, such as adequately treated cervical carcinoma in situ, non-melanoma cutaneum carcinoma, localized prostate cancer after radical operation, breast ductal carcinoma in situ after radical operation; There was also no evidence of recurrence or metastasis based on imaging and tumor markers\n11. Known history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)\n12. Patients diagnosed with nasopharyngeal carcinoma or squamous cell carcinoma whose lesions are located in parts other than the oral cavity, oropharynx, larynx and hypopharynx (such as sinuses, paranasal sinuses and unknown primary site)\n13. Participated in other clinical intervention trials or received other investigational therapies within 30 days prior to screening\n14. Patients received systemic corticosteroids (prednisone equivalent dose\\>10mg\u002Fday) or other immunosuppressive drugs within 14 days prior to randomization. If there is no active autoimmune disease, inhaled or topical steroid hormones and adrenal hormone replacement therapy with prednisone equivalent doses\\>10mg per day are permitted\n15. Pregnant or breastfeeding; Subjects of childbearing age refuse to accept contraceptive measures\n16. Patients unfit for study as assessed by the investigator\n17. Received systemic antibiotics within 1 weeks prior to first dose of study therapy or active infection requiring treatment\n18. Known history of HBV infection (defined as HBsAg positive) or active HCV infection (defined as HCV RNA detected)\n19. Has received live vaccine during study or within 30 days prior to first dose of study therapy",{"count":203,"type":20},80,[113],"A phase Ⅱ open label multi-cencter clinical trail to evaluate the efficacy and safety of pembrolizumab combined with low-dose PF (cisplatin + 5-fluorouracil) in the neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma",[207],"Head and Neck Squamous Cell Carcinoma","2025-08-14",{"date":210,"type":40},"2025-08-20",{"date":212,"type":40},"2022-09-01",{"date":39,"type":20},{"name":46,"class":47},7,{"id":217,"slug":4,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":222,"sex":16,"minAge":223,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":48},"100595492","NCT07033156","An Exploratory Study on Gene Methylation Detection of Colorectal Cancer","An Exploratory Study on Gene Methylation Detection of Colorectal Cancer（CRC）","Inclusion Criteria:\n\n1. Sample Source: Hospital physical examination, outpatient, and inpatient patients;\n2. Patient Information: Patient information (such as age, hospital ID number, gender, clinical diagnosis, colonoscopy and pathology results) is traceable;\n3. Age Requirement: ≥ 40 years old;\n4. Sampling Time Requirement: Stool and plasma samples must be collected within 3 months prior to colonoscopy (stool samples are preferred).\n\nExclusion Criteria:\n\n1. Unclear Sample Collection Information: Samples with unclear collection time, or stool samples not collected within 3 months prior to colonoscopy, or samples with incomplete clinical information that cannot be traced;\n2. Non-compliance with Sample Requirements: Samples that do not meet the collection and storage requirements;\n3. History of Disease: Subjects with a history or treatment of colorectal cancer (CRC) or advanced precancerous lesions;\n4. Insufficient Sample Volume: Samples with insufficient volume that cannot meet the requirements of the assessment system testing;\n5. Hereditary Diseases: Subjects with a diagnosis or family history of the following diseases:Familial adenomatous polyposis (FAP), including attenuated FAP and Gardner syndrome;Hereditary nonpolyposis colorectal cancer syndrome (HNPCC or Lynch syndrome);Other hereditary cancer syndromes, including but not limited to Peutz-Jeghers syndrome, MYH-associated polyposis (MAP), Turcot syndrome (or Crail syndrome), Cowden syndrome, juvenile polyposis, neurofibromatosis, or familial proliferative polyposis (FAP);\n6. Inflammatory Bowel Disease (IBD): Subjects with a diagnosis or personal history of IBD, including chronic ulcerative colitis and\u002For Crohn's disease;\n7. Cronkhite-Canada Syndrome: Subjects with a diagnosis of Cronkhite-Canada syndrome.",true,"40 Years",{"count":225,"type":20},450,"The goal of this exploration study is to evaluate the performance of a colorectal cancer (CRC) early screening model based on the DNA methylation technology platform. The study focuses on individuals over the age of 40 and aims to identify and verify methylation biomarkers for colorectal cancer using stool samples . The main question it aims to answer is:\n\nCan a DNA methylation-based model effectively detect colorectal cancer and adenoma in individuals over 40 using non-invasive stool samples?\n\nParticipants will provide stool samples for methylation analysis. The study results will be used solely for internal product performance evaluation and optimization by the sponsor and will not be used for product registration or influence any clinical diagnosis.",[228,229],"CRC (Colorectal Cancer)","Adenoma Colon","2025-06-25",{"date":232,"type":40},"2025-06-29",{"date":234,"type":40},"2024-12-24",{"date":236,"type":20},"2025-10-20",{"name":46,"class":47},{"id":239,"slug":4,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":245,"enrollmentInfo":246,"targetDuration":248,"studyType":89,"phases":4,"briefSummary":249,"conditions":250,"keywords":255,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":48},"100528706","NCT06164262","Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years","Dementia Risk rEgistry for Young And Middle-aged CSVD Patients in the Next 10 Years（DREAM-10）","DREAM-10","Inclusion Criteria:\n\n1. Patients with any of the CSVD-related MRI imaging markers, including recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and superficial cortical siderosis.\n2. Patients aged from 30 to 60 years.\n3. Sign informed consent.\n\nExclusion Criteria:\n\n1. Unable to cooperate with inspectors.\n2. Known dementia.\n3. Other cognitive diseases (such as Alzheimer's disease, Parkinson's disease, or thyroid disease).\n4. Serious systemic illness, such as heart, liver, kidney disease or major mental illness.\n5. Contraindications for imaging examination.\n\nExit Criteria:\n\n1. Not meet the inclusion criteria.\n2. For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator.\n3. Any adverse or serious adverse events during the study period judged by investigator.","60 Years",{"count":247,"type":20},1000,"10 Years","Age-related cerebral small-vessel disease (CSVD) is a major cause of dementia, predominantly affecting individuals over 60 years of age, with a prevalence exceeding 70% in the elderly population. However, the correlation between the burden of CSVD and the progression of cognitive impairment in young and middle-aged individuals remains uncertain. DREAM-10 is an observational, prospective study that enrolled individuals aged 30-60 years, who were free from known dementia but exhibited imaging markers related to CSVD. Through prospective registration and follow-up, this study will collect data on patients with CSVD, including clinical information, neuropsychological assessments, multimodal Magnetic Resonance Images (MRI) and retinopathy characterized by Optical Coherence Tomography Angiography (OCTA). CSVD related features seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, brain atrophy, cortical superficial siderosis. Utilizing this data, the researchers aim to investigate the potential dementia risk among young and middle-aged individuals with CSVD over the forthcoming decade, along with identifying its predictive factors.",[251,252,253,254],"Cerebral Small Vessel Diseases","Dementia, Mixed","Health Behavior","Health Behavior, Risky",[251,256,257],"Dementia","Cardiovascular health","2025-05-18",{"date":260,"type":40},"2025-05-21",{"date":262,"type":40},"2024-01-01",{"date":264,"type":20},"2034-12-01",{"name":46,"class":47},{"id":267,"slug":4,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":272,"minAge":17,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100591070","NCT06975644","Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)","A Prospective Clinical Study Evaluating Bemotuzumab Combined With Chemotherapy to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)","Inclusion Criteria:\n\n* 1.Voluntarily agree to participate in the clinical study and sign the informed consent form.\n* 2.Female patients aged ≥18 years at the time of signing the informed consent form.\n* 3.Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to enrollment and agree to use a clinically recognized highly effective contraceptive method during the study and for 3 months after the last dose of the study drug.\n* 4.Adequate archival tumor tissue samples for HIM-type analysis (at least 15 unstained tumor biopsy slides from the most recent metastatic lesion; archival primary tumor samples from treatment-naïve patients are acceptable, or re-biopsied specimens may be submitted).\n* 5.Primary breast cancer meeting the following criteria:Histologically confirmed invasive breast cancer.Breast cancer staging (AJCC 8th edition): T1c-4, N0-2, M0.Histopathologically confirmed triple-negative invasive breast cancer (TNBC) meeting all criteria:HER2-negative: IHC 0\u002F1+ or IHC 2+ with negative in situ hybridization (ISH).ER-negative: IHC \\\u003C1%.PR-negative: IHC \\\u003C1%.Unstained tumor sections must be submitted to the central laboratory as per the study protocol for biomarker validation.\n* 6.Willingness to undergo surgery if deemed eligible after neoadjuvant therapy.\n* 7.Adequate organ function as defined by protocol-specified laboratory thresholds.\n* 8.Eastern Cooperative Oncology Group (ECOG) performance status score ≤1 within 7 days prior to the first dose.\n\nExclusion Criteria:\n\n* 1\\. Pathological Staging a) Inflammatory breast cancer.b) Stage IV (metastatic) breast cancer, bilateral breast cancer, or multicentric breast cancer (defined as multifocal tumors involving more than one quadrant with lesions separated by ≥5 cm).\n* 2\\. Tumor-Related Conditions a) Radiologic evidence of tumor invasion into major blood vessels or investigator-determined high risk of life-threatening hemorrhage due to impending vascular compromise.b) Uncontrolled or symptomatic hypercalcemia (\\>1.5 mmol\u002FL ionized calcium, \\>12 mg\u002FdL serum calcium, or albumin-corrected serum calcium \\> upper limit of normal \\[ULN\\]); or symptomatic hypercalcemia requiring ongoing bisphosphonate therapy.c) Other severe concurrent illnesses interfering with treatment plans, including significant pulmonary conditions\u002Fdiseases.\n* 3\\. Prior\u002FConcurrent Anticancer Therapies a) Previous or current systemic antitumor therapy for the current breast cancer (including chemotherapy, molecular targeted therapy, biologic therapy, or investigational agents).b) Participation in another clinical trial within 4 weeks prior to enrollment (3 months for monoclonal antibody trials) or planned participation during this study.c) Prior treatment with immune checkpoint inhibitors other than PD-1\u002FPD-L1 monoclonal antibodies (e.g., CTLA-4 inhibitors) or anti-angiogenic agents (including monoclonal antibodies or TKIs).d) Administration of live\u002Fattenuated vaccines within 28 days before the first dose or anticipated vaccination during the study.\n* 4\\. Medical History\u002FComorbidities a) Other malignancies within the past 5 years requiring systemic\u002Flocal therapy (excluding cured carcinoma in situ, cervical intraepithelial neoplasia, basal\u002Fsquamous skin cancer, or thyroid cancer).b) Major surgery within 28 days before the first dose (defined as requiring ≥3 weeks recovery) or palliative radiotherapy\u002Fablation within 2 weeks.c) Known\u002Fsuspected autoimmune diseases, except:Hypothyroidism managed with hormone replacement.Stable type 1 diabetes with controlled glycemia.d) Active viral hepatitis:HBV: HBsAg(+) or HBcAb(+) with HBV-DNA(+) (except those with HBV-DNA ≤2,500 copies\u002FmL or 500 IU\u002FmL after antiviral therapy).HCV: HCV-Ab(+) with HCV-RNA(+).Coinfection with HBV and HCV.e) HIV infection (HIV-Ab(+)).f) Interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes, pulmonary fibrosis, acute pneumonitis).g) Severe infections:Hospital-required infections (e.g., bacteremia, pneumonia) within 4 weeks.Active CTCAE ≥Grade 2 infections requiring systemic antibiotics within 2 weeks.Unexplained fever \\>38.5°C during screening (tumor-related fever permitted per investigator).Active tuberculosis within 1 year.h) Prior allogeneic bone marrow or solid organ transplantation.i) Peripheral neuropathy ≥Grade 2 (CTCAE v5.0).j) History of neurological\u002Fpsychiatric disorders (e.g., epilepsy, dementia), drug\u002Falcohol abuse.k) Significant cardiac disease:Heart failure (LVEF \\\u003C50%).High-risk arrhythmias (resting HR \\>100 bpm, ventricular tachycardia, Mobitz II\u002Fthird-degree AV block).Unstable angina requiring antianginal therapy.Clinically significant valvular disease.ECG-confirmed transmural myocardial infarction.Uncontrolled hypertension (systolic \\>180 mmHg\u002Fdiastolic \\>100 mmHg).\n* 5\\. Treatment-Related Exclusions a) Systemic immunostimulants (e.g., interferon, interleukin-2) within 4 weeks before the first dose.b) Systemic immunosuppressants (e.g., glucocorticoids, azathioprine) within 2 weeks, except:Topical\u002Finhaled corticosteroids.Physiologic steroid replacement (≤10 mg\u002Fday prednisone equivalent).c) Hypersensitivity to study drug components or severe allergic reactions to monoclonal antibodies.\n* 6\\. Pregnancy\u002FLactation Pregnant\u002Flactating women or women of childbearing potential with positive baseline pregnancy tests or unwilling to use effective contraception.\n* 7\\. Investigator Discretion Any condition deemed by the investigator to compromise protocol compliance or patient safety.","FEMALE","80 Years",{"count":275,"type":20},55,[23],"Evaluating Bemotuzumab to improve the efficacy of neoadjuvant chemotherapy for Triple-Negative Breast Cancer (TNBC)",[279,280,281],"Triple-Negative Breast Cancer (TNBC)","Neoadjuvant Chemotherapy","Chemotherapy Effects","2025-05-17",{"date":284,"type":40},"2025-05-22",{"date":286,"type":20},"2025-09-01",{"date":288,"type":20},"2026-12-31",{"name":46,"class":47},{"id":291,"slug":4,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":296,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":48},"100591349","NCT06979271","Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis","Clinical Efficacy and Safety of Real-world Patients With Refractory Rheumatoid Arthritis (D2TRA) Receiving Telitacicept in Combination With Tofacitinib","Inclusion Criteria:\n\n1. Age 18-85 years\n2. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria\n3. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological\u002Ftargeted disease-improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients\n4. Voluntarily provided written informed consent -\n\nExclusion Criteria:\n\n1. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)\n2. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)\n3. History of allergy\u002Fhypersensitivity to the study medications (Telitacicept or Tofacitinib)\n4. Active tuberculosis or active infectious diseases requiring systemic treatment\n5. Pregnancy, lactation, or refusal to use contraception during the study\n6. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due to: Non-adherence or Severe adverse reactions\n7. Other conditions contraindicating participation per investigator judgment -",{"count":297,"type":20},20,"The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patients",[92,93,94],"2025-05-15",{"date":258,"type":40},{"date":303,"type":20},"2025-06-01",{"date":305,"type":20},"2027-04-30",{"name":46,"class":47},{"id":308,"slug":4,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":313,"targetDuration":315,"studyType":89,"phases":4,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":328,"locationsCount":48},"100588283","NCT06939387","Drug-induced Kidney Injury Model","Establishment, Evaluation and Treatment Strategy of Drug-induced Kidney Injury Model","Inclusion Criteria:\n\n* Drug-induce acute kidney injury\n\nExclusion Criteria:\n\n* 1.Dialysis patients; 2.No baseline creatinine; 3.Obstructive AKI; 4.Clinical data were incomplete.",{"count":314,"type":20},1500,"6 Months","To establish the prediction model of renal dysfunction in patients with drug-induced renal injury and study the prognosis of different drug treatments",[318],"Acute Kidney Injury",[320,321],"acute kidney injury","drug","2025-04-14",{"date":324,"type":40},"2025-04-22",{"date":326,"type":40},"2025-03-10",{"date":194,"type":20},{"name":46,"class":47},{"id":330,"slug":4,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":348,"locationsCount":48},"100588284","NCT06939400","Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence","Study on Precision Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence","Inclusion Criteria:\n\nPathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.\n\nExclusion Criteria:\n\n* Photosensitizer allergy.\n\n  * Severe coagulation disorder.\n\n    * Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.\n\n      * Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.\n\nNon-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.",{"count":336,"type":20},100,"GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.",[339],"Glioblastoma Multiforme (GBM)",[341,342,343,344],"Glioblastoma Multiforme","photodynamic therapy","metaverse","yellow fluorescence",{"date":324,"type":40},{"date":303,"type":20},{"date":175,"type":20},{"name":46,"class":47},{"id":350,"slug":4,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":272,"minAge":17,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":355,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":48},"100584554","NCT06890858","A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer","Inclusion Criteria:\n\n1. Patients voluntarily participate in the study, sign informed consent forms, and have good compliance.\n2. After platinum based chemotherapy at Zhejiang Provincial People's Hospital, the efficacy evaluation showed that ovarian cancer patients who achieved disease stability (SD) or disease progression (PD) twice were treated with Fasudil in combination with the original chemotherapy regimen, and were confirmed to have the A\u002FA genotype through genetic testing.\n\nExclusion Criteria:\n\n* 1.Accompanied by hypotension 2. Bleeding like cerebral hemorrhage 3. Patients with abnormal liver function",{"count":297,"type":20},[113],"This is a prospective study investigating whether the research on Fasudil Hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to immunotherapy in non-small cell lung cancer (NSCLC) and other tumors. The study plans to enroll 20 patients with A\u002FA genotype ovarian cancer for treatment evaluation.",[358],"Ovarian Cancer",[358,360],"Fasudil Hydrochloride","2025-03-18",{"date":363,"type":40},"2025-03-24",{"date":365,"type":20},"2025-04",{"date":367,"type":20},"2028-01",{"name":46,"class":47},{"id":370,"slug":4,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":16,"minAge":376,"maxAge":273,"enrollmentInfo":377,"targetDuration":4,"studyType":21,"phases":379,"briefSummary":380,"conditions":381,"keywords":384,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":48},"100581595","NCT06852352","An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease\u002F Parkinson's Disease","A Prospective, Single-center, Single-arm, Exploratory, 24-Month Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Subjects With Alzheimer's Disease\u002F Parkinson's Disease","SOLVEN","Inclusion Criteria:\n\nAlzheimer's disease:\n\n1. Male or female, the age ranged from 50 to 75 years old\n2. Informed consent signed and dated by patient or legal representative\n3. Patients diagnosed principally with mild cognitive impairment or dementia caused by Alzheimer's disease\n4. Positive result of Amyloid PET imaging (Centiloids ≥37)\n5. HAMD score ≤17\n6. Hachinski score ≤4 Patients who meet ASA (American Society of Anesthesiologists) grade I-III criteria\n\nParkinson's disease:\n\n1. Male or female, the age ranged from 50 to 80 years old\n2. Informed consent signed and dated by patient or legal representative\n3. Patients diagnosed with Parkinson's disease or probable Parkinson's disease according to the Clinical Diagnostic Criteria for Parkinson's Disease in China (2016) or MDS\n4. Stage I-IV patients according to Hoehn and Yahr Scale\n5. Patients documented history of Parkinson's disease for more than 2-5 years to ensure clinical stability of symptoms and exclude the possibility of early misdiagnosis of other conditions\n\nExclusion Criteria:\n\n1. Contraindications for MRI, ICG angiography, or PET scanning\n2. Contraindications for lumbar puncture\n3. Functional impairment of vital organs (cardiac, pulmonary, renal, hepatic), including reduced left ventricular ejection fraction, prolonged QT interval, severe pulmonary diseases, and severe hepatic\u002Frenal insufficiency\n4. MRI results suggesting intracranial active\u002Facute pathologies, including infections, space-occupying lesions, major hemorrhages, or ≥4 lobar microhemorrhages;\n5. Conditions predisposing to increased intracranial hemorrhage risk, such as hematological disorders, hemorrhagic\u002Fcoagulation disorders;\n6. Poorly controlled thyroid dysfunction;\n7. Cerebrovascular or systemic vasculopathy;\n8. Severe cardiac disease or hemodynamic instability;\n9. Uncontrolled severe hypertension;\n10. Substance use disorders (including illicit drugs, anesthetics, and alcohol dependence);\n11. Active severe infections, including HIV positivity and acute critical infections;\n12. Severe psychiatric disorders or significant suicide risk;\n13. Chronic hypnotic use (more than twice weekly for over one month);\n14. History of untreated\u002Funcured malignancies;\n15. Participation in other interventional clinical trials within preceding 3 months;\n16. Poor compliance with inability\u002Funwillingness to complete scheduled postoperative follow-ups;\n17. Other investigator-determined contraindications for trial participation.","50 Years",{"count":378,"type":20},160,[23],"Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by pathological protein accumulation in the brain-Aβ\u002Ftau in AD and α-synuclein in PD. Recent studies have indicated that age-related lymphatic vessel atrophy compromises the metabolic clearance capacity of meningeal lymphatic vessels, potentially disrupting the equilibrium between production and clearance of Aβ\u002Fα-synuclein, ultimately leading to pathological accumulation of these proteins within the brain. Deep cervical lymphovenous anastomosis (LVA), a surgical technique proven effective in restoring lymphatic drainage in lymphedema, may enhance clearance of neurotoxic proteins by improving cervical lymphatic outflow. This project aims to evaluate the efficacy of modified deep cervical LVA in treating AD and PD, establishing a novel therapeutic strategy to modify disease progression and improve quality of life in neurodegenerative disorders, additionally offering the pathogenic mechanisms underlying neurodegenerative disorders.",[382,383],"Alzheimer Disease","Parkinson Disease",[385],"LVA","2025-03-06",{"date":388,"type":40},"2025-03-11",{"date":390,"type":20},"2025-02-28",{"date":392,"type":20},"2028-01-31",{"name":46,"class":47},{"id":395,"slug":4,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":400,"targetDuration":4,"studyType":21,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":48},"100581897","NCT06856278","Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC","Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)","Inclusion Criteria:\n\n1. Age 18-75 years (including boundary values), male or female.\n2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.\n3. Liver and kidney function is good, and can tolerate treatment.\n4. Be able to cooperate with the completion of treatment and follow-up work.\n5. No other systemic diseases, including other malignancies.\n\nExclusion Criteria:\n\n1. Need to breastfeed the baby or have fertility needs；\n2. Immune system diseases;\n3. Diseases of the blood system;\n4. Mental system diseases;\n5. Interstitial pneumonia, lung disease, etc.;\n6. Failure to follow rules of this study.",{"count":88,"type":20},[112,113],"The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.",[404],"Anaplastic Throid Carcinoma","2025-02-26",{"date":407,"type":40},"2025-03-04",{"date":409,"type":20},"2025-02-22",{"date":411,"type":20},"2029-03-01",{"name":46,"class":47},{"id":414,"slug":4,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":272,"minAge":419,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":21,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":48},"100581037","NCT06845098","Impact of Thyroid Treatment on Ovarian Function and Pregnancy Outcomes in Women with Differentiated Thyroid Cancer","Impact of Thyroid Treatment on Ovarian Function and Pregnancy Outcomes in Women with Differentiated Thyroid Cancer: a Prospective Cohort Study","Inclusion criteria:\n\n1. Age 20-45 years old;\n2. Premenopausal women whose thyroid B-ultrasound + surgical pathology is clearly differentiated thyroid cancer (papillar thyroid cancer or follicular thyroid cancer);\n3. TNM stage is in stage I (T1-3, N0 or N1, M0);\n4. Treatment of thyroid tumor resection: unilateral lobe of the thyroid + isthmus resection, total thyroidectomy, total thyroidectomy + RAIT.\n\nExclusion criteria:\n\n1. Patients with malignant tumors in other parts or low undifferentiated thyroid cancer;\n2. Patients with abnormal liver and kidney function;\n3. TNM stage II and above;\n4. History of ovarian surgery, hysterectomy, pelvic surgery or radiation therapy;\n5. Pregnancy;\n6. Have the following uterine abnormalities, such as uterine malformation (single-horned uterus, double uterus); untreated mediastinal uterus, submucosal uterine fibroids, multiple endometrial polyps, or severe uterine adhesion.\n7. Patients diagnosed with polycystic ovary syndrome by the Rotterdam standard;\n8. Patients with ovarian failure;\n9. Patients have infectious factors, immune diseases and metabolic diseases that may affect pregnancy outcomes;\n10. Pregnancy contraindications or diseases that have a clear impact on pregnancy.","20 Years","45 Years",{"count":422,"type":20},300,[23],"This project aims to study the effects of different types of thyroid surgery and RAIT on ovarian function and pregnancy outcomes of DTC women of childbearing age, analyze possible risk factors, and assess whether potential risk factors such as age, thyroid stimulating hormone (TSH) levels and positive thyroid antibodies are related to ovarian hypofunction and adverse pregnancy outcomes.",[426],"Thyroid Gland","2025-02-19",{"date":429,"type":40},"2025-02-25",{"date":431,"type":20},"2025-02-20",{"date":44,"type":20},{"name":46,"class":47},{"id":435,"slug":4,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":16,"minAge":223,"maxAge":273,"enrollmentInfo":440,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":441,"conditions":442,"keywords":444,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":48},"100518520","NCT06031610","Revascularization Effect on CSVD Burden in Carotid Artery Stenosis","RECAS","Inclusion Criteria:\n\n1. Patients aged ≥ 40 years.\n2. ≥ 50% stenosis in unilateral carotid artery.\n3. Sign informed consent.\n\nExclusion Criteria:\n\n1. Previous history of major head trauma and any intracranial surgery\n2. Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage, and other space occupying lesions\n3. Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement.\n4. Severe loss of vision, hearing, or communicative ability.",{"count":247,"type":20},"RECAS is a prospective cohort of 1,000 patients with carotid artery stenosis (CAS) and undergoing revascularization therapy or standard medication treatment alone. The goal of this study is to validate whether CAS revascularization when compared to standard medication treatment alone, can effectively reduce the progression of Cerebral small vessel disease (CSVD) burden, as well as improve the severity of retinal pathologies and cognitive impairment. Therefore, Patients aged ≥ 40 years have more than 50% stenosis in unilateral carotid artery and sign informed consent will be recruited. In this study, patients will be asked to undergo Computed Tomography Angiography (CTA)\u002F Digital Subtraction Angiography (DSA), Computed Tomography Perfusion (CTP),multimodal Magnetic Resonance Imaging (MRI), Optical Coherence Tomography Angiography (OCTA) and neuropsychological testing. Estimated follow-up can be up to 10 years.",[443,251],"Carotid Artery Stenosis",[443,251,445,446,447],"Revascularization","Carotid artery stenting","prospective cohort","2025-02-10",{"date":450,"type":40},"2025-02-12",{"date":452,"type":40},"2023-06-10",{"date":454,"type":20},"2034-05",{"name":46,"class":47},{"id":457,"slug":4,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":462,"targetDuration":4,"studyType":21,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":471,"leadSponsor":472,"locationsCount":4},"100579276","NCT06822192","The Temporally Interfering in Patients with Disorders of Consciousness","The Efficacy and Safety of Temporally Interfering in Patients with Disorders of Consciousness","Inclusion Criteria:\n\nIn accordance with the international diagnostic criteria for MCS formulated by Giacino in 2002 or the diagnostic criteria for UWS proposed by Laureys in 2010; Patients with disease duration ≥28 days and unconscious improvement tendency in the past one month; No use of any sedative drugs or antiepileptic drugs (sodium or calcium channel blockers) in the past 1 month; stable vital signs; No obvious brain edema, hydrocephalus, and severe brain atrophy; Age from 18 to 70 years old; Informed consent was obtained from the patients' family members.\n\nExclusion Criteria:\n\nPrevious history of neurological or psychiatric disorders; Previous history of traumatic brain injury; History of cancer; Taking sedative drugs or antiepileptic drugs in the past 1 month; Unstable vital signs; Skull defect; The patients' family members did not sign the informed consent.",{"count":463,"type":20},40,[23],"This project will help the patient recover consciousness by giving TI (temporally interfering) treatment",[467],"Disorders of Consciousness","2025-02-06",{"date":450,"type":40},{"date":431,"type":20},{"date":288,"type":20},{"name":46,"class":47},{"id":474,"slug":4,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":21,"phases":480,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":48},"100556870","NCT06530732","Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)","Inclusion Criteria:\n\n* Diagnosed as an AD patient according to biological markers and clinical symptoms;\n* Over 35 years old and with an MMSE or MOCA score ≤ 26;\n* The patient or family member has signed an informed consent form.\n\nExclusion Criteria:\n\n* Inability to cooperate with lumbar puncture;\n* Cognitive impairment due to neurological infections (e.g., HIV, neurosyphilis, autoimmune encephalitis) or systemic diseases (e.g., diabetes, thyroid dysfunction);\n* Significant organ dysfunction (heart, lung, liver, kidney);\n* Coagulation disorders or contraindications to surgery;\n* Inability to fully cooperate with follow-up visits.",{"count":479,"type":20},60,[481],"PHASE3","The goal of this clinical trial is to To demonstrate the Safety and Efficacy of dcLVA Surgery for the Treatment of Alzheimer's Disease. Patients who meet the inclusion and exclusion criteria and consent to participate will be randomly assigned to either the experimental group (receiving dcLVA surgery plus standard medication) or the control group (receiving standard medication alone)\n\nParticipants will:\n\nUndergo cognitive assessment and brain MRI assessment; Undergo a lumbar puncture; Undergo an injection of 20ml of gadodiamide contrast agent at a concentration of 0.5 mmol\u002FL (1ml gadodiamide: 20ml 0.9% saline).\n\nPrimary Outcome Measures: The change in the sum of Clinical Dementia Rating Scale (CDR) scores at 12-month in relative to baseline",[484],"Alzheimer's Disease","2025-01-14",{"date":487,"type":40},"2025-01-16",{"date":489,"type":40},"2024-07-01",{"date":491,"type":20},"2026-09-30",{"name":46,"class":47},{"id":494,"slug":4,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":499,"targetDuration":4,"studyType":21,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":48},"100571642","NCT06722911","Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine As Postoperative Adjuvant Therapy in Patients with EGFR-positive Pancreatic Cancer: a Prospective, Single-arm Study","Inclusion Criteria:\n\n* 1\\. Able and willing to provide a written informed consent.\n* 2\\. Age 18-75 years old, gender unlimited;\n* 3\\. Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;\n* 4\\. Postoperative pathology suggested R0\u002FR1 resection;\n* 5\\. EGFR positive (by immunohistochemistry);\n* 6\\. KRAS gene and CDX-2 protein status must have been determined at baseline (only for post hoc analysis);\n* 7\\. Adequate organ and bone marrow function, defined as follows: absolute neutrophil count (ANC)≥1.5×10\\^9\u002FL; platelets≥80×10\\^9\u002FL; hemoglobin≥9.0 g\u002FdL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \\> 60 mL\u002Fmin;\n* 8\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n* 9\\. Postoperative survival is expected to be ≥3 months;\n* 10\\. Fertile subjects are willing to take contraceptive measures during the study period.\n\nExclusion Criteria:\n\n* 1\\. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma;\n* 2\\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n* 3\\. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP\\>160mmHg or DBP\\>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;\n* 4\\. Postoperative complications such as bleeding, pancreatic fistula, gastric obstruction, abdominal infection, and biliary fistula, which made the patient unable to receive adjuvant therapy within 12 weeks after surgery;\n* 5\\. CA199\\>180 U\u002Fml within 21d before adjuvant therapy;\n* 6\\. Known allergy to prescription or any component of the prescription used in this study;\n* 7\\. Known HIV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);\n* 8 .Other reasons that are not suitable to participate in this study according to the researcher\\'s judgment.",{"count":500,"type":20},57,[113],"This is a prospective, single-arm trial. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with nab-paclitaxel+ gemcitabine (AG regimen) for postoperative adjuvant treatment of pancreatic cancer with EGFR-positive.",[504],"Pancreatic Cancer Resectable","2024-12-04",{"date":507,"type":40},"2024-12-09",{"date":509,"type":40},"2024-11-15",{"date":511,"type":20},"2028-09-30",{"name":46,"class":47},{"id":514,"slug":4,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":519,"minAge":17,"maxAge":86,"enrollmentInfo":520,"targetDuration":4,"studyType":21,"phases":522,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":4},"100569446","NCT06694350","Pembrolizumab in Combination with Flutamide Treatment for Recurrence \u002F Metastasis HNSCC","Safety and Efficacy of Pembrolizumab in Combination with Flutamide Treatment for Advanced\u002FRecurrence \u002F Metastasis Head and Neck Squamous Cell Carcinoma: a Single-arm Clinical Study Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old, ≤ 85 years old\n2. Histologically or cytologically proven squamous cell carcinoma of the head and neck; Patients diagnosed with head and neck squamous cell carcinoma with stage III and IV A without distant metastasis according to AJCC staging (8th editon), including squamous cell carcinoma of oropharyngeal (P16-), oral cavity, hypopharyngeal and larynx\n3. Measurable primary lesions per RECIST 1.1 criteria\n4. Treatment-naive patients without any previous disease-related therapy (except for diagnostic biopsies on primary lesions)\n5. ECOG performance status of 0 or 1\n6. Unresectable primary, recurrent, and \u002F or metastatic HNSCC\n7. No active autoimmune disease\n8. No concurrent malignancy\n9. Life expectancy is estimated to be over 3 months\n10. Have sufficient tumour tissue samples available for CPS PD-L1 immunohistochemical examination (22C3 DAKO)\n11. No abvious signs of hematological disorders, ANC≥1.5×109 \u002FL, platelets ≥100×109 \u002FL, Hb≥ 90 g\u002FL,WBC ≥3.0×109 \u002FL before enrollment, no blood transfusion and bleeding tendency within 7 days\n12. ALT,AST and ALP ≤ 2.5 × upper limit of normal (ULN); Serum bilirubin ≤ 1.5 × ULN, for patients with known Gilbert disease, serum bilirubin ≤ 3 x ULN\n13. Serum creatinine ≤1.5 or creatinine clearance\\>50 mL\u002Fmin\n14. HPV status determined by p16 IHC, in situ hybridization, or by polymerase chain reaction-based assays\n15. Able to understand this study, patient and (or) legal representative voluntarily agree to participate in this trial and sign informed consent\n\nExclusion Criteria:\n\n1. Patients who are suitable for local treatment and have the intention of local treatment\n2. Received systemic treatment with Chinese patent drugs with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin) within 2 weeks before the first administration\n3. Patients with tumor progression after previous treatment with flutamide analogues (antiandrogens)\n4. Other malignant tumors occurred within 5 years or suffered from at the same time in the current period, except for cured non melanoma skin cancer or other tumors \u002F cancers that have undergone radical treatment and have no signs of disease for at least 5 years;\n5. According to the criteria of common adverse event terminology (NCI ctcaev5.0), there was peripheral neuropathy ≥ grade 2\n6. With known active central nervous system metastasis (CNS) and \u002F or cancerous meningitis\n7. Subjects who did not recover from any acute effects of previous surgery, chemotherapy or radiotherapy, i.e. did not fall to grade ≤ 1 (NCI ctcaev5.0) (excluding hair loss). Chronic late toxicity from previous radiotherapy and \u002F or surgery is allowed if nutritional status is stable\n8. Any component of the study drug or preparation has led to severe allergic reactions, including known severe allergic reactions to flutamide and (NCI ctcaev5.0 ≥ grade 3)\n9. Have received anti-tumor drug treatment (such as chemotherapy, hormone therapy, immunotherapy, antibody therapy, radiotherapy, etc.) within 4 weeks or 4 weeks before the first administration, except for palliative radiotherapy for bone to reduce pain\n10. Major surgery within 4 weeks before the first dose or expected during this study\n11. Immunosuppressive drugs were required 2 weeks or within 2 weeks before the first dose or during the study\n12. Subjects who are known to have active, or have a history of autoimmune disease that may recur\n13. Subjects with known history of interstitial lung disease, non infectious pneumonia, or high suspicion of interstitial lung disease\n14. Hepatitis B or C virological examination meets any of the following requirements at the time of screening:\n\n    1. HBsAg is positive, and the titer of hepatitis B virus deoxyribonucleic acid (HBV DNA) in peripheral blood is ≥ 104 copies \u002Fml or ≥ 2000 iu\u002Fml;\n    2. HCV antibody was positive, and HCV-RNA was higher than the detection limit of the analytical method;\n15. Within 2 weeks or 2 weeks before the first administration, the subject had active infection or uncontrollable infection requiring systemic treatment (except simple urinary tract infection or upper respiratory tract infection)\n16. Serous cavity effusion with clinical symptoms requiring clinical intervention or stabilization time less than 4 weeks\n17. Diabetes mellitus (fasting blood glucose ≥ 10mmol\u002Fl) or hypertension (systolic blood pressure ≥ 160mmhg and \u002F or diastolic blood pressure ≥ 100mmhg) with severe medical diseases, such as grade III or above cardiac dysfunction (New York Heart Association \\[nyha\\]), ischemic heart disease (such as myocardial infarction or angina pectoris) and other cardiovascular diseases, or a history of myocardial infarction within 3 months before the first administration, and still poorly controlled after drug treatment (fasting blood glucose ≥ 10mmol\u002Fl) or poorly controlled hypertension (systolic blood pressure ≥ 160mmhg and \u002F or diastolic blood pressure ≥ 100mmhg)\n18. Medical or psychiatric history or history of laboratory abnormalities that may interfere with the interpretation of the results\n19. Subjects are currently enrolled in the study of other investigational devices or investigational drugs, or are less than or equal to 4 weeks away from the discontinuation of other investigational drugs or investigational devices\n20. Subjects were known to have alcohol or drug addiction\n21. Subjects have other conditions that may affect their compliance with the protocol and evaluation of research indicators, and are not suitable to participate in the study","MALE",{"count":521,"type":20},54,[113],"This study is a single center, single arm clinical trial for newly diagnosed patients with locally advanced head and neck squamous cell carcinoma. The main purpose is to evaluate the efficacy and safety of flutamide combined with standard immunotherapy for advanced \u002F recurrent head and neck squamous cell carcinoma.\n\nIn our previous study, we found that AR can affect the occurrence and development of tumors by regulating the differentiation of cd8+t cells. We used three different castration drugs (flutamide, goserelin and abiraterone) in animal models to treat primary and tumor bearing head and neck squamous cell carcinoma mice respectively, and found that castration treatment could significantly inhibit the tumor growth of head and neck squamous cell carcinoma. In addition, in animal models, we compared the efficacy of the combination of castration therapy and low-dose cisplatin with that of the existing first-line chemotherapy drug cisplatin, and found that the combination of castration therapy and low-dose cisplatin can significantly improve the treatment effect of head and neck squamous cell carcinoma and reduce the adverse reactions brought by the drug. Therefore, we infer that flutamide combined with standard immunotherapy can fully inhibit the growth of HNSCC and improve the prognosis of HNSCC patients.",[207],[526],"HNSCC","2024-11-17",{"date":529,"type":40},"2024-11-19",{"date":531,"type":20},"2024-12",{"date":533,"type":20},"2027-12",{"name":46,"class":47},{"id":536,"slug":4,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":541,"enrollmentInfo":542,"targetDuration":4,"studyType":21,"phases":544,"briefSummary":545,"conditions":546,"keywords":548,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":555,"leadSponsor":557,"locationsCount":48},"100567924","NCT06674512","The Effectiveness of Pharmaceutical Service for INPATDRP","Evaluating the Effectiveness of Pharmaceutical Service for Inpatient with Drug-related Problems（INPATDRP）: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Hospitalized patients;\n2. Hospitalization duration \\>3 d;\n3. Adult patients aged ≥18 years and ≤100 years (only adult patients aged 18 years or older were included in the medication management study because of the difference in study methodology between minor and adult patients);\n4. Patients or close relatives gave informed consent and were willing to communicate with the clinical pharmacist and receive medication life education.\n\nExclusion Criteria:\n\n1. Those who did not meet the inclusion criteria;\n2. Patients who are in the acute phase of the disease requiring emergency medical consultation;\n3. Those with any serious or life-threatening diseases (heart, lung, liver, kidney failure, hematologic diseases, malignant tumors, etc.);\n4. Patients with psychiatric disorders, hearing impairments, intellectual disabilities, aphasia, etc. that make them unable to communicate or comply with the study protocol;\n5. Any other reasons that the investigator believes may affect the efficacy and safety evaluation of this study other reasons not suitable for participation in this clinical trial (including, but not limited to, the investigator's judgment that the subject lives far away and is unable to follow up as scheduled).","100 Years",{"count":543,"type":20},220,[23],"Medication risk is defined as the potential for loss or harm that may result from the use of medications during the course of treatment. Drug-related problems (DRPs) are defined as events or situations involving drug therapy that actually or potentially interfere with desired health outcomes. DRPs represent a significant aspect of medication risk in hospitalized patients, and the study and management of DRPs can effectively reduce the incidence of medication risk. DRPs are associated with both therapeutic efficacy and adverse drug events, and the timely identification and reduction of DRPs can enhance clinical efficacy and prevent the occurrence of adverse events.\n\nDRPs pose a challenge to the clinician, and that may affect patient's clinical outcomes and may result in morbidity or mortality and increased health care costs. Health care costs may become a burden to the patient or may be to the government or to the third parties. Clinical Pharmacy is a discipline that promotes the quality use of medicines through evidence-based medicine and helps in identification and resolving DRPs. A clinical pharmacist through his\u002Fher clinical accuracy checking may identify DRPs and come out with suitable solutions to resolve the same.\n\nConsequently, the aims of our study were to investigate the efficacy and safety effects of pharmacist-implemented drug-related problems (DRPs)-based interventions on patients' medication therapy.",[547],"Drug Related Problem",[547,549,550],"Inpatient","Clinical Pharmacist","2024-11-03",{"date":553,"type":40},"2024-11-05",{"date":531,"type":20},{"date":556,"type":20},"2026-06",{"name":46,"class":47},{"id":559,"slug":4,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":582},"100557361","NCT06537115","Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia","Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia：a RCT Trial","Inclusion Criteria:\n\n* Age 30 or above;\n\n  * Meeting the diagnostic criteria for sarcopenia according to the definition of AWGS; ③ Able to walk, willing to accept a comprehensive intervention plan, and guarantee to complete the treatment course; ④ Both patients and their families agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Resting systolic blood pressure \\> 200 mmHg or resting diastolic blood pressure \\> 100 mmHg;\n\n  * Severe heart disease: moderate to severe aortic valve stenosis, acute pericarditis, acute myocarditis, myocardial infarction, uncontrollable arrhythmia;\n\n    * Acute stroke within the past 2 years;\n\n      * Severe airway obstruction;\n\n        * Lower limb fractures in the past 1 year or upper limb fractures in the past 6 months;\n\n          * Hypercalcemia (corrected albumin serum calcium \\> 2.60 mmol\u002FL);\n\n            * Active malignant tumors; ⑧ Chronic kidney disease stages 5;\n\n              * Mental illness or severe cognitive impairment;\n\n                * Long-term immobilization; ⑪ Other diseases that may interfere with the evaluation of muscle mass, muscle strength, and physical function; ⑫ Unable to cooperate with treatment due to other reasons; ⑬ Life expectancy less than 6 months.",{"count":225,"type":20},[142],"This clinical trial is a multicenter, single-blind, prospective, randomized controlled clinical application study. Subjects who met the trial criteria and signed the informed consent form were randomly divided into a control group, an experimental group 1, and an experimental group 2. After enrollment, the control group underwent a comprehensive assessment of their underlying conditions by professional physicians and received routine interventions, including basic nutritional intervention program guidance, progressive resistance exercise intervention program guidance, safety precautions, and symptomatic treatment for different complications, for a total intervention period of 24 weeks. The experimental group 1, in addition to the interventions provided to the control group, received whey protein powder supplementation for 12 weeks. The experimental group 2, on the other hand, received both whey protein powder and eldecalcitol supplementation on top of the interventions given to the control group, also for 12 weeks. The entire intervention period lasted for 24 weeks. Through regular general assessments, blood tests, measurements of muscle mass, muscle strength, and physical function, as well as analyses of negative adverse events, statistical methods were employed to evaluate the safety and efficacy of the comprehensive intervention methods for sarcopenia.",[568],"Sarcopenia",[568,570,571,572,573],"intervention","idecalcitol","whey protein powder","exercise","2024-08-02",{"date":576,"type":40},"2024-08-05",{"date":578,"type":40},"2024-06-16",{"date":580,"type":20},"2027-05-31",{"name":46,"class":47},5,""]